Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
AGGF1P3 is a processed pseudogene located on chromosome 16, derived from the parent gene AGGF1. Unlike active genes, processed pseudogenes like AGGF1P3 are formed through retrotransposition and lack introns, making them typically nonfunctional and incapable of producing protein products. While some pseudogenes can influence biological processes via RNA-mediated regulation of their parent genes, AGGF1P3 itself is not documented to have such a function and is not considered a therapeutic target. In summary, AGGF1P3 is not a conventional biomedical target; it is a noncoding pseudogene with no established role as a receptor, enzyme, transporter, or drug target. If structured information or research intended to focus on gene targets for therapy or diagnostics, AGGF1P3 should be excluded or flagged as non-relevant.
None known; pseudogenes rarely have direct mechanisms of action in drug response.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Angiogenic factor with G-patch and FHA domains 1 pseudogene 3 (AGGF1P3).